In addition, it must be remembered that mutational status is not the only prognostic factor that influences the clinical outcome of patients with GIST on receptor tyrosine kinase therapy, with initial low tumor volume, female gender, and CD34 positivity predicting higher PFS in a recent study considering patients treated with imatinib [36]. The gene discussed is NTRK1; the disease is gastrointestinal stromal tumor.